Loading organizations...
§ Private Profile · London, United Kingdom
thymia is a technology company.
Thymia develops a foundational voice biomarker platform designed to enhance mental health assessment and monitoring. The company utilizes advanced technology and clinical expertise to create more objective, faster, and reliable tools for mental healthcare. Their platform analyzes voice data, aiming to provide measurable insights across various health domains, including mental, respiratory, cardiovascular, and metabolic health.
Thymia was co-founded by Dr. Emilia Molimpakis, who serves as CEO, and Gabrielle Powell. Their initial insight stemmed from a desire to introduce objectivity into mental health assessment, moving beyond subjective evaluations to more quantifiable data. Dr. Molimpakis is noted for her expertise in the field, guiding the company's scientific and technological direction from its inception.
The platform serves healthcare providers and aims to improve the diagnostic and monitoring processes for individuals experiencing mental health conditions. Thymia's long-term vision is to transform mental healthcare by integrating cutting-edge technology and rigorous research, thereby providing a more precise and data-driven approach to understanding and managing mental well-being globally.
thymia has raised $4.0M across 2 funding rounds.
Key people at thymia.
thymia has raised $4.0M in total across 2 funding rounds.
thymia has raised $4.0M across 2 funding rounds. Most recently, it raised $3.0M Seed in July 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 1, 2023 | $3M Seed | Alexander Kuznetsov | Calm/Storm Ventures, Sequel, Starther, Henrik Herr, Johann "hansi" Hansmann, Omid Ashtari, Rosaleen Blair, Amanda Cardinale, Nadav Rosenberg, Entrepreneur First, Form Ventures, Syndicate Room | Announced |
| Jun 1, 2021 | $1M Seed | Calm/Storm Ventures, Kodori Ventures | Henrik Herr, Johann "hansi" Hansmann, Entrepreneur First, Form Ventures | Announced |
Key people at thymia.
Thymia is a London-based health technology company founded in 2020 that develops AI-powered platforms to objectively measure and monitor mental health conditions, making mental health as trackable as physical metrics like blood pressure.[1][2] Its products, such as Helios for wellness (assessing burnout, stress, mental strain, tiredness, and confidence) and Apollo for clinical use (targeting depression, anxiety, ADHD; Apollo launching fully in 2025), serve healthcare providers, payers, employers, and wellness platforms globally across five continents.[1][2][5] By analyzing voice, video, facial expressions, movements, and behavioral data via gamified app-based activities, Thymia addresses the global mental health crisis—affecting over a billion people, with 75% lacking access—enabling efficient triaging, diagnosis, treatment, and early detection of issues like stress and burnout.[2][3][4] The company has shown strong growth, raising £2.7m in seed funding from Kodori Ventures and £1.1m via Crowdcube, expanding its data network toward half a billion patients, and earning recognition as a top London scaleup for 2025.[1][4]
Thymia was co-founded in 2020 in London by a team leveraging expertise in AI, machine learning, neuropsychology, and mental health, with key operations now spanning the UK, Greece (Athens office expansion), Europe, Canada, Latin America, India, and the US.[1][2] The idea emerged from the need to objectively assess mental health—starting with depression—using innovative digital biomarkers, inspired by the founders' recognition that over a billion people suffer from poor mental health without accessible measurement tools.[1][4] Early traction came swiftly: the startup secured £2.7m in seed funding led by Kodori Ventures, followed by £1.1m via Crowdcube, built an exclusive global dataset (the largest of its kind combining voice, video, and behavior), and rolled out products internationally by 2023, including AI platforms tested across cultures.[1][2][4] Pivotal moments include featuring in Sifted's reports on Greece's tech scene and City A.M.'s "10 London scaleups to watch in 2025," highlighting its rapid evolution into a multinational player.[1][4]
Thymia's standout advantages stem from its proprietary AI technology and global scalability:
Thymia rides the AI-in-healthcare wave, specifically the explosion in digital biomarkers and remote mental health monitoring, accelerated by post-pandemic awareness of the global mental health crisis (1B+ affected, 75% untreated).[2][4] Timing is ideal amid rising demand for scalable, objective tools amid clinician shortages and workplace wellness mandates, with market forces like AI advancements in multimodal data (voice/video/behavior) and regulatory nods for investigational devices favoring rapid adopters.[1][2] It influences the ecosystem by democratizing mental health data—expanding networks to represent diverse populations (e.g., via Greek engineering for global scale)—pushing competitors toward similar innovations and enabling payers/providers to cut costs via early intervention.[1][4] As part of London's thriving scaleup scene and Greece's emerging tech hub, Thymia amplifies Europe's healthtech footprint against US giants.[1][4]
Thymia is primed for explosive growth in 2025+, with Apollo's full clinical launch, Helios API expansions, and data network targeting half a billion patients via Athens scaling and global partnerships.[1][2] Trends like AI ethics regulations, workplace mental health mandates, and multimodal biomarkers will propel it, potentially unlocking Series A funding and pharma collaborations for drug trials.[2][4] Its influence could evolve from niche innovator to category leader, redefining mental health as quantifiable and proactive—echoing its mission to track state of mind like a thermometer, ultimately bridging the access gap for a billion people.[2]
thymia has raised $4.0M in total across 2 funding rounds.
thymia's investors include Alexander Kuznetsov, Calm/Storm Ventures, sequel, StartHer, Henrik Herr, Johann "Hansi" Hansmann, Omid Ashtari, Rosaleen Blair, Amanda Cardinale, Nadav Rosenberg, Entrepreneur First, Form Ventures.
